Here are the Form 4 insider transactions from Pacira BioSciences, Inc. (PCRX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PCRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PCRX filings page.
Pacira BioSciences, Inc. completed its merger effective November 17, 2026. CEO Frank D. Lee’s 660,830.841 reported common shares, including RSUs and 1,022.077 shares acquired under the Employee Stock Purchase Plan, converted into a right to receive the $36.50-per-share offer price, net of applicable withholding taxes and without interest.
Lee’s 692,512 options, with a $32.07 exercise price, were canceled and converted into a cash right based on any excess of the offer price over the exercise price, subject to withholding. Lee reported zero shares and options afterward; Pacira continued as a wholly owned subsidiary of Viatris.
Pacira BioSciences, Inc. director Alethia Young disposed of 17,798 common shares, including restricted stock unit awards, on November 17, 2026, when the merger became effective. The shares converted into the right to receive $36.50 per share, net of applicable withholding taxes and without interest, and her reported direct holdings fell to zero. Four option positions were canceled and converted into cash rights based on the excess, if any, of the offer price over the exercise price, subject to tax withholding; options with exercise prices at or above the offer price were canceled without consideration. Pacira continued as a wholly owned subsidiary of Viatris.
Pacira BioSciences, Inc. director Samit Hirawat reported dispositions at the November 17, 2026, effective time of the merger, which made Pacira a wholly owned subsidiary of Viatris. His 6,405 common shares, including RSU awards, converted into the right to receive $36.50 per share; his reported resulting balance was zero. Options covering 10,891 shares at a $23.42 exercise price and 39,291 shares at $19.85 were canceled and converted into cash rights based on the excess, if any, of the offer price over each exercise price, subject to tax withholding.
Pacira BioSciences, Inc. director Michael J. Yang reported dispositions on November 17, 2026, when the merger with Viatris became effective. Under the tender offer, 13,393 common shares were converted into the right to receive $36.50 per share. A further 6,405 shares issuable under restricted stock units were canceled for cash based on the offer price, subject to tax withholding. Four option awards covering 12,179, 11,279, 10,891 and 30,967 shares were canceled and converted into cash based on any excess of the offer price over each exercise price, subject to withholding. Options priced at or above the offer price were canceled without consideration; Pacira continued as a wholly owned subsidiary of Viatris.
Pacira BioSciences, Inc. Chief Administrative Officer Kristen Williams disposed of 167,062 common shares on November 17, 2026, in the merger. Each share converted into the right to receive $36.50 per share, net of applicable withholding taxes and without interest; her reported common-stock holding afterward was zero. Her reported options were canceled at the merger’s effective time; each listed exercise price exceeded the offer price, so the options were canceled with no consideration. No Rule 10b5-1 plan is reported.
Pacira BioSciences, Inc. chief commercial officer Brendan Teehan reported that 100,934 shares of common stock were disposed of on November 17, 2026, when each share converted into the right to receive the merger offer price of $36.50 per share, net of applicable withholding taxes and without interest. His reported common-stock balance afterward was zero. At the merger’s effective time, his options covering 99,500 shares, with a $26.59 per-share exercise price, were canceled and converted into a cash amount based on the excess, if any, of the offer price over the exercise price, subject to applicable tax withholding; the reported option balance afterward was zero. Pacira survived the merger as a wholly owned subsidiary of Viatris.
Pacira BioSciences, Inc. became a wholly owned subsidiary of Viatris Inc. on November 17, 2026, after Peach Purchaser Sub Inc. completed a cash tender offer and merged into Pacira. Director Christopher Christie disposed of 16,654 common shares, each converted into the right to receive $36.50 per share, net of applicable withholding taxes and without interest.
At the merger’s effective time, Christie's restricted stock units covering 6,405 shares were canceled and converted into cash based on the offer price, subject to tax withholding. His options were canceled; options with exercise prices below $36.50 per share converted into cash based on the positive difference between the offer price and exercise price, while options at or above that price were canceled for no consideration. No Rule 10b5-1 plan is reported.
Pacira BioSciences, Inc. CFO Shawn Cross reported three merger-related dispositions on November 17, 2026. His 9,210 common shares became a right to receive $36.50 per share, net of withholding and without interest; his RSU award covering 86,591 shares was canceled and converted to cash at the offer price, subject to tax withholding. His 150,000 options with a $16.45 exercise price were canceled for cash based on the excess, if any, of the offer price over the exercise price; his reported option position afterward was zero. Pacira became a wholly owned Viatris subsidiary.
Pacira BioSciences, Inc. (PCRX) director Mark Froimson reported the disposition of 20,136 common shares on November 17, 2026, in Viatris’ cash tender offer at $36.50 per share, net of applicable withholding taxes and without interest. At the merger’s effective time that day, 6,405 restricted stock units were canceled and converted into a cash right based on the shares issuable and the $36.50 offer price, subject to tax withholding. Nine option positions were canceled: options with exercise prices below the offer price converted into cash rights based on the difference between those prices; options at or above the offer price were canceled for no consideration. Pacira became a wholly owned subsidiary of Viatris.
Pacira BioSciences, Inc. (PCRX) director Marcelo Bigal reported dispositions on November 17, 2026, in connection with the Viatris merger. He disposed of 11,393 common shares in the cash tender offer at $36.50 per share, net of applicable withholding taxes and without interest. His 6,405 shares issuable under restricted stock unit awards were canceled and converted into cash, subject to tax withholding.
Four option awards were canceled and converted into cash based on the excess, if any, of the $36.50 offer price over each exercise price: 12,179 options at $28.68; 11,279 at $24.34; 10,891 at $23.42; and 30,967 at $29.80 per share.
Pacira BioSciences, Inc. director Thomas G. Wiggans disposed of a directly held stock option covering 32,675 shares on November 17, 2026, the merger’s effective date. The option was canceled and converted into a cash right calculated using the $36.50 per-share offer price less its $23.42 per-share exercise price, subject to applicable tax withholding. Wiggans reported zero options remaining after the transaction.
Pacira BioSciences, Inc. (PCRX) Senior Vice President, Finance Lauren Riker reported merger-related dispositions on November 17, 2026, when the cash tender offer and merger became effective. Her 6,881 shares were converted into the right to receive $36.50 per share, net of applicable withholding taxes and without interest. Another 55,403 shares issuable under restricted stock unit awards were canceled and converted into a right to receive cash based on the $36.50 offer price, subject to tax withholding. The reported options had exercise prices above $36.50 and were canceled without consideration.
Pacira BioSciences, Inc. director Laura Brege disposed of 23,715 common shares in the cash tender offer on November 17, 2026, at $36.50 per share. The offer was part of Viatris Inc.’s acquisition; at the merger’s effective time, Pacira became Viatris’ wholly owned subsidiary.
Her 6,405 restricted stock unit award shares were canceled and converted into a cash right based on the $36.50 offer price, subject to tax withholding. Ten option tranches were canceled and converted into cash only where the offer price exceeded the exercise price; options with exercise prices at or above $36.50 were canceled for no consideration.
Pacira BioSciences, Inc. Chief Medical Officer Jonathan Slonin reported a disposition to the issuer of 216,729.67 common shares at the $36.50-per-share offer price on November 17, 2026, when the merger became effective; his reported direct holdings afterward were zero. Each share converted into a right to receive the offer price, net of applicable withholding taxes and without interest. No Rule 10b5-1 plan is reported.
The report also lists six option positions disposed of in connection with the merger. Options with exercise prices below $36.50 were canceled and converted into cash based on the difference between the offer price and exercise price; options at or above $36.50 were canceled without consideration. Pacira survived the merger as a wholly owned subsidiary of Viatris.
Pacira BioSciences, Inc. (PCRX) reported that Chief Financial Officer Shawn Cross had 9,540 common shares withheld by the issuer on October 30, 2026, to cover tax withholding obligations upon vesting of a restricted stock unit award. The transaction was classified as a tax-withholding disposition.
Pacira BioSciences, Inc. (PCRX) Senior Vice President, Finance Lauren Riker exercised options for 6,000 common shares on October 8, 2026, at an exercise price of $32.35 per share, then sold 6,000 shares at $36.32 per share. The exercise and sale were made under a Rule 10b5-1 trading plan adopted March 12, 2026. The reported option position after the exercise was 0 shares, and the option's expiration date was December 7, 2026.
Pacira BioSciences, Inc. (PCRX) reported that its Chief Medical Officer, Jonathan Slonin, sold 3,040 shares of common stock on August 17, 2026 at $23.23 per share in an open-market transaction. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2025. Following this sale, Slonin directly holds 216,383.646 shares of Pacira common stock, which include 511.471 shares acquired through the company’s employee stock purchase plan in June 2026.
Pacira BioSciences director Samit Hirawat received new equity awards. He was granted 6,405 restricted stock units of common stock, which will vest on June 10, 2027 if he remains in continuous service with the company through that date.
He was also granted stock options covering 10,891 shares of common stock at an exercise price of $23.42 per share. These options vest and become exercisable on June 10, 2027, and expire on June 10, 2036. Following these awards, he holds 6,405 common shares and options on 10,891 shares directly.
Pacira BioSciences, Inc. Senior Vice President of Finance Lauren Riker sold 6,115 shares of common stock in an open-market transaction at $23.50 per share. After the sale, she directly held 62,284.242 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026.
Pacira BioSciences director Christopher Christie received new equity compensation awards. He was granted 6,405 restricted stock units that vest on June 10, 2027, as long as he remains in continuous service with the company through that date. Each unit represents one share of common stock. He also received a stock option for 10,891 shares of common stock at an exercise price of $23.42 per share, which vests and becomes exercisable on June 10, 2027 and expires on June 10, 2036. Following these awards, Christie directly holds 23,059 shares of Pacira common stock. These are compensation-related grants, not open-market purchases or sales.
Pacira BioSciences director Thomas G. Wiggans received a stock option grant for 32,675 shares of common stock. The option has an exercise price of $23.42 per share and expires on June 10, 2036. One-third of the option vests on the first anniversary of the grant, with the remaining shares vesting in equal monthly installments over the following two years, as long as he remains in continuous service. After this grant, he holds options for 32,675 shares.
Pacira BioSciences director Alethia Young reported receiving equity compensation. On June 10, 2026, she was granted 6,405 restricted stock units, each representing one future share of common stock, and 10,891 stock options with an exercise price of $23.42 per share.
Both the restricted stock units and options vest on June 10, 2027, provided she remains in continuous service with Pacira through that date. Following the grant, she directly holds 17,798 shares of common stock, plus the newly granted options for 10,891 additional shares.
Pacira BioSciences director Michael J. Yang received new equity awards as part of his compensation. On June 10, 2026, he was granted 6,405 restricted stock units that will vest on June 10, 2027, if he remains in continuous service. Each unit converts into one share of common stock at vesting.
He also received a stock option for 10,891 shares of common stock at an exercise price of $23.42 per share. This option becomes exercisable on June 10, 2027, subject to the same service requirement, and expires on June 10, 2036. Following these awards, he directly holds 19,798 shares of common stock.
Pacira BioSciences director Marcelo Bigal received new equity awards as part of compensation. He was granted 6,405 restricted stock units, each representing one share of common stock, which vest on June 10, 2027 if he remains in continuous service with the company.
He also received a stock option covering 10,891 shares of common stock at an exercise price of $23.42 per share. This option vests on June 10, 2027 under the same service condition and expires on June 10, 2036. Following the grant, his direct holdings of common stock total 17,798 shares.
Pacira BioSciences director Mark Froimson received equity compensation consisting of restricted stock units and stock options. He was granted 6,405 restricted stock units, each representing the right to receive one share of Pacira common stock. These units vest on June 10, 2027, if he remains in continuous service through that date, and will then convert into common shares.
He was also granted 10,891 stock options to buy Pacira common stock at an exercise price of $23.42 per share. These options vest and become exercisable on June 10, 2027, subject to the same continuous service condition, and expire on June 10, 2036. Following the grant, Froimson directly holds 26,541 shares of Pacira common stock.
Pacira BioSciences director Laura Brege reported equity awards consisting of restricted stock units and stock options. She received 6,405 shares of common stock as a grant, bringing her directly held common shares to 30,120. She was also granted options for 10,891 shares at an exercise price of $23.42 per share.
The 6,405 restricted stock units vest on June 10, 2027, if she remains in continuous service with Pacira through that date. The stock options also vest on June 10, 2027 under the same service condition and will expire on June 10, 2036 if not exercised.
Pacira BioSciences Senior Vice President of Finance Lauren Riker reported a routine tax-related share disposition. On a restricted stock unit vesting, 3,187 shares of common stock were withheld by the company to cover tax obligations at $22.32 per share. After this withholding, Riker directly holds 68,399.242 shares of Pacira common stock, indicating the transaction was a standard compensation-related event rather than an open-market sale.
Pacira BioSciences, Inc. Chief Medical Officer Jonathan Slonin reported a routine tax-related share disposition. On the reported date, 4,728 shares of common stock were withheld by the company to cover tax obligations when a restricted stock unit award vested. After this withholding, Slonin directly holds 218,912.175 shares of Pacira BioSciences common stock. This event reflects tax withholding rather than an open-market sale or purchase.
Pacira BioSciences Chief Administrative Officer Kristen Williams sold 10,259 shares of common stock in an open-market trade at $22.27 per share on June 4, 2026. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 10, 2025.
One day earlier, on June 3, 2026, 8,528 shares were withheld at $22.32 per share to cover tax obligations upon vesting of a restricted stock unit award, which is a non-market, compensation-related event. After these transactions, Williams directly holds 167,062 Pacira shares.
Pacira BioSciences Chief Financial Officer Shawn Cross reported option-related transactions in company common stock. On April 23, 2026, he exercised stock options to acquire 12,941 shares at $16.45 per share and sold 12,941 shares in open-market trades at a weighted average price of $25.16, within a range of $25.00 to $25.41. The filing shows these moves were made under a pre-established Rule 10b5-1 trading plan. After the transactions, he directly owned 105,341 shares of Pacira common stock.
Pacira BioSciences Chief Financial Officer Shawn Cross exercised stock options and sold shares in a pre-planned set of trades. Over April 20–22, he exercised options for 12,059 shares of common stock at an exercise price of $16.45 per share and sold the same number of shares in open-market transactions at weighted average prices around $25.01–$25.14 per share.
After these transactions, he directly holds 105,341 shares of Pacira common stock. The filing states that the option exercises and sales were carried out under a previously adopted Rule 10b5-1 trading plan, indicating the trades were pre-scheduled rather than opportunistic.
Pacira BioSciences director Mark A. Kronenfeld received an equity award of 6,163 restricted stock units on June 11, 2025. The grant was at no cash cost per share and increases his direct holdings to 31,065 common shares equivalents.
The units vest on June 11, 2026, only if he remains in continuous service with Pacira through that date. Each restricted stock unit converts into one share of Pacira common stock upon vesting, reflecting standard, service-based director compensation rather than an open-market purchase or sale.
Pacira BioSciences Chief Medical Officer Jonathan Slonin sold 3,261 shares of common stock in an open-market transaction at a price of $22.82 per share on March 17, 2026. After this sale, he directly holds 223,640.175 shares of Pacira common stock.
The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan that Slonin previously adopted, indicating the sale was scheduled in advance rather than timed discretionarily.
Pacira BioSciences, Inc. director Mark Froimson reported an open-market sale of 500 shares of common stock at $21.81 per share. After this transaction, he directly holds 20,136 shares. This filing reflects a relatively small sale compared with his remaining reported ownership.
Pacira BioSciences Chief Financial Officer Shawn Cross was granted 49,091 restricted stock units of common stock on February 11, 2026. The award was reported at a price of $0 per share as an acquisition, increasing his directly held common stock to 105,341 shares.
The restricted stock units vest in four equal annual installments beginning on February 15, 2027, if Cross remains in continuous service with Pacira on each vesting date. Each unit represents the right to receive one share of Pacira common stock upon vesting.
Pacira BioSciences Chief Administrative Officer Kristen Williams received an equity award of 54,546 shares of common stock on February 11, 2026. The award is in the form of restricted stock units granted at a price of $0 per share, described as a grant, award, or other acquisition.
These restricted stock units vest in four equal annual installments beginning on February 15, 2027, as long as she remains in continuous service with the company on each vesting date. Each unit represents the right to receive one share of Pacira common stock. Following this grant, Williams beneficially owns 185,849 shares of Pacira common stock directly.
Pacira BioSciences, Inc. reported an equity award to Chief Commercial Officer Brendan Teehan. On February 11, 2026, he acquired 51,714 shares of common stock at a price of $0 under a grant classified as an award or other acquisition.
The award represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, as long as he remains in continuous service with the company on each vesting date. After this grant, Teehan directly beneficially owns 100,934.268 shares of Pacira common stock.
RIKER LAUREN reported acquisition or exercise transactions in a Form 4 filing for PCRX. The filing lists transactions totaling 19,273 shares. Following the reported transactions, holdings were 71,586 shares.
SLONIN JONATHAN reported acquisition or exercise transactions in this Form 4 filing.
Pacira BioSciences, Inc. reported that Chief Medical Officer Jonathan Slonin received an equity award of 54,546 shares of common stock on February 11, 2026. The award was granted at a price of $0 per share and is structured as restricted stock units.
These restricted stock units vest in four equal annual installments beginning on February 15, 2027, as long as Slonin remains in continuous service with the company on each vesting date. After this grant, he beneficially owns 226,901.175 shares of Pacira common stock directly.
Pacira BioSciences, Inc. reported an equity award to its Chief Executive Officer and director, Frank D. Lee. On February 11, 2026, he acquired 261,818 shares of common stock in the form of restricted stock units granted at a price of $0 per share.
These restricted stock units vest in four equal annual installments beginning on February 15, 2027, as long as he remains in continuous service with the company on each vesting date. Following this grant, Lee beneficially owns 660,830.841 shares of Pacira common stock directly.
Pacira BioSciences, Inc. Senior Vice President of Finance Lauren Riker reported routine equity transactions in company stock. On January 30, 2026, 2,751 shares of common stock were withheld by Pacira to cover tax obligations upon vesting of a restricted stock unit award at $20.54 per share. On February 2, 2026, Riker sold 4,000 shares of common stock at a weighted average price of $20.81 per share, executed under a pre-established Rule 10b5-1 trading plan. After these transactions, Riker directly beneficially owned about 52,313.242 shares of Pacira common stock.
Pacira BioSciences Chief Administrative Officer Kristen Williams reported two stock transactions. On January 30, 2026, 17,134 shares of common stock were withheld by Pacira to cover tax obligations upon vesting of a restricted stock unit award at a price of $20.54 per share, leaving her with 144,440 shares held directly.
On February 2, 2026, she sold 13,137 Pacira common shares at $20.53 per share in a transaction carried out under a pre-established Rule 10b5-1 trading plan. After this sale, she directly held 131,303 Pacira shares.
Pacira BioSciences Chief Medical Officer reports tax-share withholding. Jonathan Slonin, Chief Medical Officer of Pacira BioSciences, Inc., reported a Form 4 transaction involving company common stock. On 01/30/2026, 6,168 shares of common stock were withheld by Pacira to cover tax obligations when a restricted stock unit award vested at a price of $20.54 per share.
After this withholding, Slonin directly beneficially owned 172,355.175 shares of Pacira common stock. The transaction reflects tax-related share withholding rather than an open-market sale.
Pacira BioSciences, Inc. reported a routine insider tax-withholding transaction by its Chief Commercial Officer, Brendan Teehan. On 01/30/2026, 5,182 shares of common stock were withheld by the company at $20.54 per share to cover tax obligations upon vesting of a restricted stock unit award. After this withholding, Teehan directly beneficially owned 49,220.268 shares of Pacira common stock.
Pacira BioSciences, Inc. CEO Lee Frank D. reported an automatic share withholding related to equity compensation. On January 30, 2026, 41,488 shares of common stock were withheld by Pacira at $20.54 per share to cover tax obligations on a vested restricted stock unit award.
After this tax withholding, Lee Frank D. directly beneficially owned 399,012.841 shares of Pacira common stock. The transaction reflects routine administration of equity compensation rather than an open-market trade.
Pacira BioSciences, Inc. director Samit Hirawat received a grant of stock options on January 27, 2026. The award covers 39,291 stock options with an exercise price of $19.85 per share, held directly, and represents a right to buy common stock.
According to the vesting terms, one-third of the options vest on the first anniversary of the grant date. The remaining options vest in equal monthly installments over the following two years, as long as the director continues in service. The options expire on January 27, 2036.
Pacira BioSciences Chief Medical Officer Jonathan Slonin reported an automatic share withholding related to equity compensation. On January 2, 2026, 381 shares of Pacira common stock were withheld at $24.46 per share to cover tax obligations when a restricted stock unit award vested. After this withholding, Slonin beneficially owned 178,523.175 shares of Pacira common stock, which includes 537.166 shares acquired through the company’s employee stock purchase plan in December 2025. This filing reflects routine tax and ownership reporting rather than an open-market trade.
Pacira BioSciences Senior Vice President of Finance Lauren Riker reported two stock transactions in early January 2026. On January 2, 2026, 159 shares of Pacira common stock were withheld by the company at $24.46 per share to cover tax obligations when a restricted stock unit award vested. On January 5, 2026, Riker sold 1,416 shares of common stock at a price of $24.24 per share under a pre‑established Rule 10b5‑1 trading plan. After these transactions, Riker directly owned 59,064.242 shares of Pacira common stock, which includes 1,075.242 shares acquired through the company’s employee stock purchase plan in December 2025.
Pacira BioSciences Chief Commercial Officer Brendan Teehan acquired additional company stock through an employee purchase plan. On 12/31/2025, he obtained 402.268 shares of Pacira common stock at a price of $10.763 per share under the issuer's employee stock purchase plan.
After this transaction, Teehan directly beneficially owned a total of 54,402.268 shares of Pacira common stock, reflecting his ongoing equity participation as an executive officer.